Thrombophilia due to thrombin defect

This study tests whether the blood thinner apixaban can dissolve blood clots in the portal vein that develop more than a year after laparoscopic spleen surgery in people with cirrhosis. Twenty participants will take apixaban twice daily, and doctors will use ultrasound or CT scan…

This study looks at whether the blood thinner apixaban can safely dissolve blood clots in the portal vein (the main vein to the liver) that appear more than a year after spleen removal surgery. It involves 20 adults with cirrhosis who had their spleen removed. The goal is to see …

This study looks at cancer patients who have a type of blood clot called superficial venous thrombosis (SVT). About 15-20% of SVTs happen in people with cancer, but there are no clear treatment guidelines for them. Researchers will observe 1,576 patients to see how different bloo…

This study is testing whether patients recovering from hip or knee replacement can safely skip elastic compression stockings and rely only on blood-thinning drugs to prevent dangerous blood clots. Over 1,200 participants will be randomly assigned to receive either drugs plus stoc…

This study looks at two types of blood thinners—direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs)—to see which works better at preventing repeat blood clots in people with a low-risk form of antiphospholipid syndrome (APS). APS is an autoimmune condition that ra…

This study looks at how blood cells interact and what goes wrong in inherited bleeding disorders like Glanzmann thrombasthenia. Researchers will analyze blood samples from up to 60 healthy volunteers and patients to find genetic defects. The goal is to better understand these con…

This study looks at why cancer patients have a much higher risk of developing blood clots. Researchers will collect blood clots from 120 patients (with and without cancer) who undergo a procedure to remove clots. They will analyze the clots for cancer cells and other factors to b…